Institut für Experimentelle Pneumologie
  1. Startseite LMU Klinikum
  2. Experimental Pneumology
  3. Prof. Dr. Markus Diefenbacher

Prof. Dr. Markus Diefenbacher

Arbeitsgruppenleiter

Professur für Immunonkologie der Lunge und Pleura (Stiftungsprofessur)

Curriculum Vitae

Markus Elmar
Diefenbacher

Univ.-Professor, Dr. rer.nat.
d.o.b. April 19th, 1978, in Karlsruhe, Germany

University Education

10.2023
2009
1997-2004

Univ. Prof. Experimental Pneumology (LMU) and Helmholtz Research Group Experimental Oncology
Dr. rer. nat., KIT
Studies of Biology, University of Karlsruhe and Helmholtz Zentrum Karlsruhe/Karlsruhe Institute of Technology (KIT)

Scientific Career

Since 2023
Since 2023
2020-2023
2015-2023
2015-2023
2009-2015

Univ. Prof. Experimental Pneumology (LMU) and Helmholtz Research Group Experimental Oncology, Munich, Germany
Affiliated Editor at Oncogene
Founding member of the Mildred Scheel Junior Research Center Würzburg
Junior Group Leader, Biocenter University Würzburg
Junior Group Leader, Comprehensive Cancer Center Würzburg
Postdoctoral Fellow, Cancer Research UK London Research Institute and The Francis Crick Institute, Mammalian Genetics Department, London, UK

Citation Record

Total citations: 2.135; h-index:21; h-index since 2017: 19(Google Scholar December 05th, 2023)

Top-10 selected Publications

Senior author papers:

  1. Hartmann O, Reissland M, Maier CR, Fischer T, Prieto-Garcia C, Baluapuri A, Schwarz J, Schmitz W, Garrido-Rodriguez M, Pahor N, Davies CC, Bassermann F, Orian A, Wolf E, Schulze A, Calzado MA, Rosenfeldt MT, Diefenbacher ME (2021) Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease. Front Cell Dev Biol 9: 641618
  2. Prieto-Garcia C, Hartmann O, Reissland M, Braun F, Bozkurt S, Pahor N, Fuss C, Schirbel A, Schulein-Volk C, Buchberger A, Calzado Canale MA, Rosenfeldt M, Dikic I, Munch C, Diefenbacher ME (2022a) USP28 enables oncogenic transformation of respiratory cells, and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K. Mol Oncol 16: 3082-3106
  3. Prieto-Garcia C, Hartmann O, Reissland M, Braun F, Fischer T, Walz S, Schulein-Volk C, Eilers U, Ade CP, Calzado MA, Orian A, Maric HM, Munch C, Rosenfeldt M, Eilers M, Diefenbacher ME (2020) Maintaining protein stability of ΔNp63 via USP28 is required by squamous cancer cells. EMBO Mol Med 12: e11101
  4. Prieto-Garcia C, Hartmann O, Reissland M, Fischer T, Maier CR, Rosenfeldt M, Schulein-Volk C, Klann K, Kalb R, Dikic I, Munch C, Diefenbacher ME (2022b) Inhibition of USP28 overcomes Cisplatin-resistance of squamous tumors by suppression of the Fanconi anemia pathway. Cell Death Differ 29: 568-584
  5. Fischer T, Hartmann O, Reissland M, Prieto-Garcia C, Klann K, Pahor N, Schulein-Volk C, Baluapuri A, Polat B, Abazari A, Gerhard-Hartmann E, Kopp HG, Essmann F, Rosenfeldt M, Munch C, Flentje M, Diefenbacher ME (2022) PTEN mutant non-small cell lung cancer require ATM to suppress pro-apoptotic signalling and evade radiotherapy. Cell Biosci 12: 50
  6. Maier, C. R., O. Hartmann, C. Prieto-Garcia, K. M. Al-Shami, L. Schlicker, F. C. E. Vogel, S. Haid, K. Klann, V. Buck, C. Munch, W. Schmitz, E. Einig, B. Krenz, M. A. Calzado, M. Eilers, N. Popov, M. T. Rosenfeldt, M. E. Diefenbacher and A. Schulze (2023). "USP28 controls SREBP2 and the mevalonate pathway to drive tumour growth in squamous cancer." Cell Death Differ 30(7): 1710-1725.

    Contributing author papers:
  7. Mainz L, Sarhan M, Roth S, Sauer U, Kalogirou C, Eckstein M, Gerhard-Hartmann E, Seibert HD, Voelker HU, Geppert C, Rosenwald A, Eilers M, Schulze A, Diefenbacher M, Rosenfeldt MT (2022a) Acute systemic knockdown of Atg7 is lethal and causes pancreatic destruction in shRNA transgenic mice. Autophagy 18: 2880-2893
  8. Mainz L, Sarhan M, Roth S, Sauer U, Maurus K, Hartmann EM, Seibert HD, Rosenwald A, Diefenbacher ME, Rosenfeldt MT (2022b) Autophagy Blockage Reduces the Incidence of Pancreatic Ductal Adenocarcinoma in the Context of Mutant Trp53. Front Cell Dev Biol 10: 785252
  9. Novak R, Ahmad YA, Timaner M, Bitman-Lotan E, Oknin-Vaisman A, Horwitz R, Hartmann O, Reissland M, Buck V, Rosenfeldt M, Nikomarov D, Diefenbacher ME, Shaked Y, Orian A (2022) RNF4~RGMb~BMP6 axis required for osteogenic differentiation and cancer cell survival. Cell Death Dis 13: 820
  10. Ruiz EJ, Diefenbacher ME, Nelson JK, Sancho R, Pucci F, Chakraborty A, Moreno P, Annibaldi A, Liccardi G, Encheva V, Mitter R, Rosenfeldt M, Snijders AP, Meier P, Calzado MA, Behrens A (2019) LUBAC determines chemotherapy resistance in squamous cell lung cancer. J Exp Med 216: 450-465